Capricor Therapeutics, Inc. (CAPR)

Capricor’s main catalyst remains the Food and Drug Administration’s November 22 decisionon deramiocel for preserving upper-limb function in Duchenne muscular dystrophy. Recent two-year data showed slower functional decline, but the prior negative advisory vote and unresolved statistical concerns keep approval expectations divided.[1][2][3]